DUBLIN--(BUSINESS WIRE)--The "Global Schizophrenia Drugs Market Analysis 2019" report has been added to ResearchAndMarkets.com's offering.
The Schizophrenia Drugs market is expected to reach $10.16 billion by 2026 growing at a CAGR of 4.5% during 2018 to 2026.
Factors such as increased demand for enhanced therapy among patients, improvement in healthcare infrastructure, and rise in R&D expenditure in the field of medicine are driving the market growth. Though, social stigma of mental health conditions restrains the market growth. Moreover, rising healthcare expenditure is the opportunity for the schizophrenia drugs market.
Based on therapeutic class, the second-generation segment is going to have a lucrative growth during the forecast period, as it is the most commonly preferred medication. Also, it is FDA approved for acute treatment of manic or mixed episodes of bipolar disorder, maintenance treatment of the bipolar disorder and irritability associated with autistic disorders.
The key vendors mentioned are Eli Lilly, Johnson & Johnson, Pfizer, Bristol-Myers Squibb, Vanda Pharma, Otsuka Pharma, Alkermes, Sumitomo Dainippon, Allergan, AstraZeneca, Titan Pharmaceutical, Alexza Pharmaceuticals, Novartis, Yoshitomi Yakuhin Corporation, Braeburn Pharmaceuticals, and Merck & Co.
Key Questions Answered in this Report
- How this market evolved since the year 2016
- Market size estimations, forecasts and CAGR for all the segments presented in the scope
- Key Market Developments and financials of the key players
- Opportunity Analysis for the new entrants
- SWOT Analysis of the key players
- Fastest growing markets analysed during the forecast period
Key Topics Covered
1 Market Synopsis
2 Research Outline
2.1 Research Snapshot
2.2 Research Methodology
2.3 Research Sources
2.3.1 Primary Research Sources
2.3.2 Secondary Research Sources
3 Market Dynamics
3.1 Drivers
3.2 Restraints
4 Market Environment
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Schizophrenia Drugs Market, By Type
5.1 Introduction
5.2 Catatonic Schizophrenia
5.3 Disorganized Schizophrenia
5.4 Paranoid Schizophrenia
5.5 Schizoaffective Disorder
6 Global Schizophrenia Drugs Market, By Therapeutic Class
6.1 Introduction
6.2 First-Generation
6.3 Second-Generation
6.4 Third-Generation
7 Global Schizophrenia Drugs Market, By Treatment Type
7.1 Introduction
7.2 Antipsychotics
7.3 Coordinated Specialty Care (CSC)
7.4 Psychosocial Treatments
7.5 Thioxanthenes
7.6 Oral
7.7 Injectables
8 Global Schizophrenia Drugs Market, By Application
8.1 Introduction
8.2 Unipolar Depression
8.3 Bipolar Disorder
8.4 Schizophrenia
8.5 Dementia
9 Global Schizophrenia Drugs Market, By End User
9.1 Introduction
9.2 Hospital Pharmacies
9.3 Clinics
9.4 Rehabilitation Centers
9.5 E-Commerce
9.6 Drug Stores/Retail Pharmacies
10 Global Schizophrenia Drugs Market, By Geography
10.1 North America
10.2 Europe
10.3 Asia-Pacific
10.4 South America
10.5 Middle East & Africa
11 Strategic Benchmarking
12 Vendors Landscape
12.1 Eli Lilly
12.2 Johnson & Johnson
12.3 Pfizer
12.4 Bristol-Myers Squibb
12.5 Vanda Pharma
12.6 Otsuka Pharma
12.7 Alkermes
12.8 Sumitomo Dainippon
12.9 Allergan
12.10 AstraZeneca
12.11 Titan Pharmaceutical
12.12 Alexza Pharmaceuticals
12.13 Novartis
12.14 Yoshitomi Yakuhin Corporation
12.15 Braeburn Pharmaceuticals
12.16 Merck & Co.
For more information about this report visit https://www.researchandmarkets.com/r/ku7ker
